Türk Klinik ve Laboratuvar Dergisi Cilt 2 : Sayı 2

Öz

Anahtar Kelimeler

• -

Kaynakça

1. Öncül O. Hastane kökenli gram negatif çomaklarda direnç. XXXI. Türk Mikrobiyoloji Kongresi, Kongre Kitabında, 2004; s:94-6.
2. Gür D, Ünal S ve ark. Yoğun bakım ünitelerinde izole edilen gram negatif bakterilerin çeşitli antibiyotiklere in vitro duyarlılıkları . Flora Dergisi 1996;1:153-9.
3. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta- lactamases: the quiet before the storm? Clin Microbiol Rev. 2005 ;18: 25. Review.
4. Giske CG, Libisch B, Colinon C, et al. Establishing clonal relati- onships between VIM-1-like metallo-beta-lactamase-producing Pseu- domonas aeruginosa strains from four European countries by multilo- cus sequence typing. J Clin Microbiol. 2006 ;44 : 4309-15.
5. Nouer SA, Nucci M, Oliveira MP, et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo- beta-lactamase. Antimicrob Agents Chemother. 2005 ;49:3663-7.
6. Bal Ç. Metallo Beta laktamazlar ve Klinik Önemi. XII.TÜRK Kli- nik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi Kongre Kitabın- da. Antalya; 2005:146.
7. Yong D, Choi YS, Roh KH, et al. Increasing prevalence and diversity of metallo-beta-lactamases in Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae from Korea. Antimicrob Agents Chemother. May;50(5):1884-6.
8. Bellais S, Mimoz O, Leotard S, et al. Efficacy of β-lactams for trea- ting experimentally induced pneumonia due to a carbapenem hydroy- zing matallo-β-lactamase-producing strains of Pseudomonas aerugino- sa. Antimicrob Agents Chemother. 2002 ;46(6):2032-4.

9. Fiett J, Batraniak A, Mrowka A, et al. Molecular epidemiology of ac- quired mettalo-β-lactamase producing bacteria in Poland. Antimicrobi- al Agents and Chemotherapy 2006; 50:880-6.
10. Sanchez A, Salso S, Culebras E, Picazo JJ. Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas ae- ruginosa. Rev. Esp Quimioter ; 2004; 17:336-40.
11. Gupta V, Datta P, Chander J. Prevalence of metallo-beta lactamase (MBL) producing Pseudomonas spp. and Acinetobacter spp. in a terti- ary care hospital in India. J Infect. 2006 May;52(5):311-4.
12. Lagatolla C, Tonin EA, Monti-Bragadin C, et al. Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo- beta-lactamase determinants in European hospital. Emerg Infect Dis. ; 10:535-8. Laupland KB, Parkins MD, Church DL, et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importan- ce of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis. ;192:1606-12.
13. Lee K, Lee WG, Uh Y, et al. VIM- and IMP-type metallo-beta- lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Ko- rean hospitals. Emerg Infect Dis 2003;9:868.
14. Navaneeth BV, Sridaran D, Sahay D, Belwadi M. A preliminary study on mettalo β-lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res 2002; 116: 264-8.
15. Lolans K, Queenan AM, Bush K, et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta- lactamase (VIM-2) in the United States. Antimicrob Agents Chemot- her. 2005 ; 49:3538-40.
16. Toraman ZA, Yakupogulları Y, Kizirgil A. Detection of metallo beta-lactamase production and antibiotic resistance with E-test method in Pseudomonas, Acinetobacter and Klebsiella strains, in Turkey. J In- fect Chemother. 2004; 10:257-61.
17. Bahar G, Mazzariol A, Koncan R, et al. Detection of VIM-5 metallo- ß-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother. 2004;54:282-3.
18. Bayraktar B, Yıldız D, Bulut E. Yoğun bakım ünitesinden izole edi- len karbapeneme dirençli Pseudomonas aeruginosa suşlarında metal- lobetalaktamaz üretiminin araştırılması. Türk Mikrobiyoloji Cemiyeti Dergisi 2004; 34:248-252.
19. Limoncu MH, Ermertcan Ş, Çavuşoğlu C, Eraç B. Hastane infek- siyonlarından izole edilen Pseudomonas aeruginosa ve Acinetobacter kökenlerinde metallo-beta-laktamaz varlığının araştırılması. Türk Mik- robiyoloji Cemiyeti Dergisi 2006; 36: 79-82.
20. Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A. Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical tes- ting. J Clin Microbiol. 2002 ;40:2755-9.
21. E-test katalogu, AB Biodisk, Sweeden. Aktas Z, Bal C, Midilli K,et al. First IMP-1-producing Klebsiella pneumoniae isolate in Turkey. Clin Microbiol Infect. 2006 ; 12:695-6.
22. Lee K, Lim YS, Yong D, et al. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo- beta-lactamase-producing isolates of Pseudomonas spp. and Acineto- bacter spp. J Clin Microbiol. 2003 ; 41: 4623-9.
23. Yong D, Lee K, Yum JH, Shin HB, et al. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clini- cal isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Micro- biol 2002;40:3798-801.
24. Aktaş Z, Kayacan CB. Investigation of metallo-beta-lactamase pro- ducing strains of Pseudomonas aeruginosa and Acinetobacter bauman- nii by E-test, disk synergy and PCR. Scand J Infect Dis. 2008; 40:320-5.
25. Ozgumus OB, Caylan R, Tosun I, Sandalli C, Aydin K, Koksal I. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey. Microb Drug Resist. 2007 ;13:191-8.
26. Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-β- lactamase producing Pseudomonas aeruginosa. Indian J Med Microbi- ol. 2008;26:233-7. Teşekkür
27. Anane S, Kallel K,. Kaouech E, Belhaj S and Chaker F. Candida dubliniensis: a novel emerging species, Ann. Biol. Clin. 2007; 65:13-9.
28. Pfaller MA, and Diekema DJ. Rare and emerging opportunistic fun- gal pathogens: concern for resistance beyond Candida albicans and As- pergillus fumigatus. J. Clin. Microbiol. 2004; 42:4419-31.
29. Neppelenbroek KH, Campanha NH, Spolidorio DM. Molecular fin- gerprinting methods for discrimination between C. albicans and C. dub- liniensis. Oral Dis 2005;12:242-53.
30. Shokohi T, Hashemi, Soteh MB, Saltanat Pouri Z, Hedayati MT, Mayahi S. Identification of Candida species using PCR-RFLP in cancer patients in Iran. Indian J. Med. Microbiol. 2010; 28: 147-51.
31. Wilson DA, Joyce MJ, Hall LS et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J. Clin. Microbiol. 2005; 43:2909-12.
32. Ruiz-Sanchez D, Calderon-Romero L, Sanchez-Vega JT, Tay J. Intes- tinal candidiasis. A clinical report and comments about this opportunis- tic pathology. Mycopathologia. 2002; 156: 9-11.
33. Pinjon E, Moran GP, Coleman DC, Sullivan DJ. Azole suscepti- bility and resistance in. Candida dubliniensis. Biochem. Soc. Trans. ;33:1210-14.
34. Tulumoğlu Ş, Karıptaş E, Erdem B. Identification and antifungal sus- ceptibility of Candida isolates from various clinical specimens in Doc- tor Behçet Uz Hospital. Anatol. J. Clin. Investig. 2009; 3:170-3.
35. Akortha EE, Nwaugo VO, Chikwe NO Antifungal resistance among Candida species from patients with genitourinary tract infection isolated in Benin City, Edo state, Nigeria Afr. J. Microbiol. Res. 2009; :694-9.
36. Su C, Meyer SA. Characterization of mitochondrial DNA in various Candida species: isolation, restriction endonuclease reaction, size and base composition. Int. J. Syst. Bacteriol. 1991; 41:6-14.
37. Seyer A, Yaman M, Khalil I, et al.. The evaluation of the morphol- ogy of Candida species on different agar plates. Turkish Microbiologi- cal Society. 2009; 39: 69-72.
38. Dealler, SF. Candida albicans colony identification in 5 minutes in a general microbiology laboratory. J. Clin. Microbiol. 1991; 29:1081-2.
39. Park BG, Lee MK. Appopriate condition of Germ tube formation as presumptive identification test for Candida albicans. Korean J. Med. Mycol. 2008; 13: 20-5.
40. Baradkar VP, Mathur M, Kumar S. Hichrom candida agar for identi- fication of Candida species. Indian J. Pathol. Microbiol. 2010; 53:93-5.
41. Yucesoy M, Esen N, Yulug N. Use of chromogenic tube and methyl blue-sabouraud agar for the identification of Candida albicans strains. Kobe J. Med. Sci. 2001; 47: 161-7.
42. Larone, DH. Medically important fungi: a guide to identification, th ed., ASM Press, Washington, D.C; 2002.
43. Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 1996; 34: 58-61.
44. Hospenthal DR, Murray CK, Beckius ML, Green JA, Dooley DP. Persistence of pigment production by yeast isolates grown on CHRO- Magar Candida media. J. Clin. Microbiol. 2002; 40: 4768-70.
45. Rippon, JW. Candidiasis and the pathogenic yeasts. In: JW. Rippon (ed), Med Mycol, PA, , pp 532-81. 1988.
46. Calderone, RA.. Candida and candidiasis. ASM Press, Washington D.C; 2002.
47. Momani OM. Cost-effectiveness and efficacy of CHROMagar Candida medium in clinical specimens. J. East Mediterr. Health 2000; :968-78.
48. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet In- fect. Dis. 2003; 3:685-702.
49. Zarrin M Jamshidian M, Jafari M.. In vitro interactions of mico- nazole with sulfametoxazole against Candida species. Pak J Med Sci.; ; 25: 243-6. Uppuluri P, Chaturvedi AK, Srinivasan A, et al. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 2010; 3:6:e1000828.
50. Hoog, GS, Guarro, J, Gene J, Figueras MJ. Atlas of clinical fungi, nd ed. Centraalburearu voor Schimmelcultures / Universitat Rovia i Virgili, Utrecht, The Netherlands; 2000.
51. Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. In PR Murray et al. (ed.) Manual of Clinical Microbiology. Ch. 114. 8th ed. ASM Press. Washington, DC. 2003. p. 711.
52. Molero G, Díez-Orejas R, Navarro-García F et al. Candida albicans: genetics, dimorphism and pathogenicity. Internatl. Microbiol. 1988. 1: 106.
53. Selvarangan R, Limaye AP, Cookson BT. Rapid identification and differentiation of Candida albicans and Candida dubliniensis by capil- lary-based amplification and fluorescent probe hybridization. J. Clin. Microbiol. 2002; 40: 4308-12.
54. Coleman D, Sullivan D, Harrington B et al. Molecular and phe- notypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis. 1997; 1:96-101.
55. Sullivan D, Coleman D. Minireview. Candida dubliniensis: charac- teristics and identification. J. Clin. Microl. 1998; 36:329-34.
56. Nucci M, Colombo AL. Candidemia due to Candida tropicalis: clin- ical, epidemiologic and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn. Microbiol. Infect. Dis. 2007; : 77–82.
57. Zaugg C, M. Zepelin B, Reichard D, Sanglard D, Monod M. Se- creted aspartic proteinase family of Candida tropicalis. Infect. Immun. ; 69:405-12. Jonathan, L, Hager MD, Mohsin R, Mir MD, Sylvia Hsu MD. Can- dida krusei fungemia in an immunocompromised patient Dermatology Online Journal. 2010; 16 (4): 5.
58. Samaranayake LP. Candida krusei infections and fluconazole thera- py. Hong Kong Med. J. 1997; 3: 312-4.
59. Murray, PR., Baron, EJ, Jorgensen, JH., Landry, ML, Pfaller, MA. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole suscepti- bility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 2004; :11-23.
60. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerg- ing fungal pathogen. Clin Microbiol Rev 2008; 21: 606-25.
61. Kreger-Van Rij, NJW. The Yeasts: a taxonomic study. 3rd Edition. Elsevier Science Publishers B.V., Amsterdam, The Netherlands; 1984.
62. Macêdo DPC, Silva VKA, Farias AMA, Melo LRB, Wilheim AB, Neves RP. Candida glabrata esophagitis: new case reports and manage- ment. Braz. J. Microbiol. 2008; 39:1-7.
63. Fidel PL, Vazquez JA, Sobel JD. Candida glabrata: review of epi- demiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 1999; 12:80-96.
64. Pfaller MA, Diekema DJ, Mendez M, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to flu- conazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol.; 2006; 44: 3551-6.
65. Johnson EM. Rare and emerging Candida species. Clin. Fungal. Infect. Reports 2009; 3:152-9.
66. Tsang PW, Wong K. Chu JK. Isolation and characterization of Can- dida kefyr orotidine-5_-phosphate decarboxylase (URA3) gene. Yeast ; 27: 53-8. Hawkins JL, Baddour LM.. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis. 2003; 15;36(2):14-8.
67. Sandven P, Nilsen K, Digranes A, Tjade T, Lassen J. Candida nor- vegensis: a Fluconazole-Resistant Species. Antimicrob. Agents Chem- other. 1997; 41: 1375-6.
68. Khan, ZU, Al Sweih NA, Ahmad S, et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to ampho- tericin B, itraconazole, and fluconazole. J. Clin. Microbiol. 2007; :2025-7.
69. Diekema, DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global col- lection of rare Candida species as determined by CLSI broth microdilu- tion methods. J. Clin. Microbiol.2009; 47:3170-7.
70. Corresponding Author: Ilknur Dag Eskisehir Osmangazi University Electron Microscope Laboratory Eskisehir-TURKEY Phone: [phone] 63 E-mail: [e-mail] Asymptomatic Tracheal Fistula to Adjacent Soft Tissue Secondary to Blunt Trauma Nurdan CAY, Karabekir ERCAN2, Meral ARİFOĞLU2, Muharrem TOLA Department of Radiology, Yuksek Ihtisas Education and Research Hospital, Ankara- TURKEY Department of Radiology, Ataturk Education and Research Hospital, Ankara- TURKEY Chappell VL, Heck HA Jr. Repair of large, iatrogenic, tracheo-es- ophageal fistulae. Ann Thorac Surg 2007;83:705-6.
71. Priestley JD, Berkowitz RG. Closure of tracheocutaneous fistula in children. Int J Pediatr Otorhinolaryngol 2006;70:1357-9.
72. Raghavendran K, Cherr GS, Ford PF, Burkhard PG, Bell-Thomson J. Successful management of concomitant aortoesophageal and aortotra- cheal fistulae secondary to a thoracic aortic aneurysm: case report and review of literature. J Vasc Surg 2005;42:1218-20.
73. Reed MF, Mathisen DJ. Tracheoesophageal fistula. Chest Surg Clin N Am 2003;13:271-89.
74. Lam WW, Tam PK, Chan FL, Chan KL, Cheng W. Esophageal atresia and tracheal stenosis: use of three-dimensional CT and virtual bronchoscopy in neonates, infants, and children. AJR Am J Roentgenol ;174:1009-12.
75. Yedururi S, Guillerman RP, Chung T, Braverman RM, Dishop MK, Giannoni CM, Krishnamurthy R. Multimodality imaging of tracheo- bronchial disorders in children. Radiographics 2008;28:e29.
76. Address for correspondence: Nurdan Cay, M.D. Yasamkent Mah. 3222. Cad. Blok (Yakut) No: 37 D: 27
77. Berenholz LP, Segal S, Kessler A. Goitre presenting as an orophary- ngeal mass: an unusual finding in the elderly. The Journal of Laryngo- logy and Otology. 1999; 113(2):170-1.
78. Kenyon GS, Robb PJ. Hashimato’s disease presenting as an unusual retropharyngeal mass. Clinical Oncology 1981; 9:159-164.
79. Atasoy Ç, Karagülle AT, Akyar S. Multinodular goiter presenting as a retropharyngeal mass: a case report. Journal of Ankara Medical Scho- ol. 2002;24(2): 87-90.
80. Govindaraj S, Rezaee R., Pearl A., Som P.M., Urken M.L. Radiology Quiz Case. Arch Otolaryngol Head Neck Surg. 2003; 129(9):1013-4.
81. Soboroff BJ. An unusual retropharyngeal mass. Transactions of the American Academy of Ophtalmology and Otolaryngology. 1977; :136-8.
82. Dalgıç N, Ergenekon E, Bideci A, Erbaş G, Koç E, Talı T, Atalay Y. Congenital retropharyngeal goiter in a newborn as a magnetic resonan- ce imaging finding. Pediatrics International 2001; 43:431-3.
83. Paleri V, Maroju RS, Ali MS, Ruckley RW. Spontaneous retro-and parapharyngeal haematoma caused by intrathyroid bleed. The Journal of Laryngology and Otology. 2002; 116(10): 854-8.
84. Chrobok V, Celakovsky P, Nunez-Fernandez D, Simakova E, Acute purulent thyroiditis with retropharyngeal and retrotracheal abscesses. Journal of Laryngology and Otology. 2000; 114(2): 151-3.
85. DiLeo M, Baker KB, Deschler DG, Hayden RE. Metastatic papil- lary thyroid carcinoma presenting as a retropharyngeal mass. American Journal of Otolaryngology. 1998; 19(6): 404-6.
86. Mercante G, Gabrielli E, Pedroni C, Formisano D, Berolini L, Ni- coli F, Valcavi R, Barbieri V. Head Neck. 2010; Aug 24 (Epub ahead od print).
87. Raffaelli M, DE Crea C, Ronti S, Bellantone R, Lombardi CP. Subs- ternal goiters: Incidence, surgical approach, and complications in a terti- art care referral center. Head Neck. 2010; Nov 10 (Epub ahead od print).
88. Sorumlu Yazar: Bige SAYIN sokak Yazıkırı sitesi B-2 Blok No:12 Ümitköy/Ankara- TÜRKİYE Tel: [phone] E-mail: [e-mail] Macias-Robles MD, Peliz MG, Gonzalez-Ordonez AJ. Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks. Blood Coagul Fibrinolysis 2005;16:217-9.
89. Jabr FI. Rectal sheath hematoma in an elderly woman after antico- agulation treatment. J Am Geriatr Soc 2006;54:871-2.
90. Torres GM, Cernigliaro JG, Abbitt PL, Mergo PJ, Hellein VF, Fer- nandez S, Ros PR. Iliopsoas compartment: normal anatomy and patho- logic processes. Radiographics 1995;15:1285-97.
91. McCort JJ. Intraperitoneal and retroperitoneal hemorrhage. Radiol Clin North Am 1976;14:391-405.
92. Rimola J, Perendreu J, Falcó J, Fortuño JR, Massuet A, Branera J. Percutaneous arterial embolization in the management of rectus sheath hematoma. AJR Am J Roentgenol. 2007 Jun;188(6):W497-502.
93. Olgu sunumlarının giriş ve tartışma kısımları kısa-öz olmalı, kaynak sayısı 15 den az olmalıdır. Kısa raporlara özet yazılmamalı, en fazla 5 adet anahtar kelime, 10 kaynak, 1500 kelime, 2 tablo ve/veya şekil olma- lı ve yazının hemen sonunda sırasıyla yazar isimleri, ünvanları ve yazışma adresleri bulunmalıdır.
94. Editöre mektup, dergide daha önce yayımlanmış yazılara bilimsel eleştiri yapmak, katkı sağlamak ya da orjinal bir ça- lışma olarak sunulmamış veya sunulamayacak bilgilerin paylaşılması amacıyla hazırlanmış en fazla 1000 kelimeden olu- şan, kısa-öz ve 6 dan az sayıda kaynağı olmalı özet içermemelidir.